GRAMMER ELIZABETH A
Known title: See RemarksCIK: 0001213041
GRAMMER ELIZABETH A's purchase track record
GRAMMER ELIZABETH A has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/31/2022 | ARDX | $2K | +81.4% | +208.0% | -0.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ARDX | ▼ Sell | Open Market | 5,995 | $33K | 11/21/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 5,841 | $35K | 8/21/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 5,992 | $24K | 5/20/2025 | View on chart |
| ARDX | ▲ Buy | Grant | 136,680 | $0 | 2/25/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 4,291 | $24K | 2/20/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 7,046 | $34K | 11/20/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 7,089 | $42K | 8/20/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 6,927 | $54K | 5/21/2024 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 110,250 | $109K | 5/6/2024 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 109,687 | $302K | 5/6/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 219,937 | $2.0M | 5/6/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 64,233 | $570K | 5/6/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 45,000 | $405K | 5/3/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 86,000 | $665K | 3/20/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 4,432 | $39K | 2/20/2024 | View on chart |
| ARDX | ▲ Buy | Grant | 127,750 | $0 | 1/16/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 50,000 | $254K | 12/11/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,384 | $10K | 11/20/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,392 | $8K | 8/21/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,384 | $9K | 5/23/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,914 | $9K | 2/21/2023 | View on chart |
| ARDX | ▲ Buy | Grant | 78,000 | $0 | 1/5/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 20 | $39 | 11/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,193 | $2K | 11/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 29 | $56 | 11/22/2022 | View on chart |
| ARDX | ▲ Buy | Open Market | 3,000 | $2K | 8/31/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,225 | $1K | 8/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 2 | $2 | 8/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 9 | $9 | 8/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 59,561 | $39K | 6/6/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,260 | $801 | 6/6/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,263 | $848 | 5/20/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,528 | $1K | 2/22/2022 | View on chart |
| ARDX | ▲ Buy | Grant | 42,000 | $0 | 1/6/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 537 | $533 | 11/22/2021 | View on chart |
| ARDX | ▼ Sell | Open Market | 77,432 | $87K | 11/12/2021 | View on chart |
| ARDX | ▲ Buy | Grant | 250,000 | $0 | 10/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Ardelyx shares IBSRELA real-world data at ACG 2026
Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.
Ardelyx shares IBSRELA real-world data at ACG 2026. Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.